Incorporating appropriate assays along with the traditional biomarkers in clinical decision-making still remains a challenge as all available tools have advantages and limitations that the clinicians should understand and explain to patients.
Breast cancer is the most common malignancy in women in the United States and is second only to lung cancer as a cause of cancer death. The treatment of breast cancer is rapidly evolving.
These NCCN Guidelines Insights highlight the updated recommendations for use of multigene assays to guide decisions on adjuvant systemic chemotherapy therapy for women with hormone receptor-positive, HER2-negative early-stage invasive breast cancer.
The goal of this activity is to improve participants' knowledge of, confidence in, and competence in integrating PARP inhibitors into treatment of patients with breast cancer.
The goal of this activity is to improve participants' knowledge of, confidence in, and competence in integrating PARP inhibitors into treatment of patients with breast cancer.
NCCN is pleased to host this webinar on the topic of "Barriers to the Coordination of Cancer Care" in the NCCN 2018 Congress Series: Breast Cancer with Updates from the 2017 San Antonio Breast Cancer Symposium (SABCS).
Facebook
X
LinkedIn
Forward
